Skip to main content

Table 1

From: High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine

Therapy

IL-2

IL-2 + Vaccine

Portion female

58%

59%

Median age at diagnosis

50 yrs

40 yrs

Median age at IL-2

54 yrs

44 yrs

Median age at vaccine

N/A

47

Median survival from IL-2

12.8 mos

40.3 mos

5-year survival from IL-2

14%

44%

Back to article page